Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

Similar articles for PubMed (Select 24496038)

1.

SR48692 inhibits non-small cell lung cancer proliferation in an EGF receptor-dependent manner.

Moody TW, Chan DC, Mantey SA, Moreno P, Jensen RT.

Life Sci. 2014 Mar 28;100(1):25-34. doi: 10.1016/j.lfs.2014.01.072. Epub 2014 Feb 2.

2.

Downregulation of ubiquitin inhibits the proliferation and radioresistance of non-small cell lung cancer cells in vitro and in vivo.

Tang Y, Geng Y, Luo J, Shen W, Zhu W, Meng C, Li M, Zhou X, Zhang S, Cao J.

Sci Rep. 2015 Mar 30;5:9476. doi: 10.1038/srep09476.

3.

Structural dynamics and thermostabilization of neurotensin receptor 1.

Lee S, Bhattacharya S, Tate CG, Grisshammer R, Vaidehi N.

J Phys Chem B. 2015 Apr 16;119(15):4917-28. doi: 10.1021/jp510735f. Epub 2015 Apr 7.

PMID:
25807267
4.

Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest.

Kriegs M, Gurtner K, Can Y, Brammer I, Rieckmann T, Oertel R, Wysocki M, Dorniok F, Gal A, Grob TJ, Laban S, Kasten-Pisula U, Petersen C, Baumann M, Krause M, Dikomey E.

Radiother Oncol. 2015 Apr;115(1):120-7. doi: 10.1016/j.radonc.2015.02.018. Epub 2015 Mar 18.

PMID:
25796091
5.

CI-988 Inhibits EGFR Transactivation and Proliferation Caused by Addition of CCK/Gastrin to Lung Cancer Cells.

Moody TW, Nuche-Berenguer B, Moreno P, Jensen RT.

J Mol Neurosci. 2015 Jul;56(3):663-72. doi: 10.1007/s12031-015-0533-6. Epub 2015 Mar 12.

PMID:
25761747
6.

Neurotensin promotes the progression of malignant glioma through NTSR1 and impacts the prognosis of glioma patients.

Ouyang Q, Gong X, Xiao H, Zhou J, Xu M, Dai Y, Xu L, Feng H, Cui H, Yi L.

Mol Cancer. 2015 Feb 3;14:21. doi: 10.1186/s12943-015-0290-8.

7.

Fangchinoline as a kinase inhibitor targets FAK and suppresses FAK-mediated signaling pathway in A549.

Guo B, Su J, Zhang T, Wang K, Li X.

J Drug Target. 2015 Apr;23(3):266-74. doi: 10.3109/1061186X.2014.992898. Epub 2014 Dec 24.

PMID:
25539072
8.

Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib.

Younes M, Wu Z, Dupouy S, Lupo AM, Mourra N, Takahashi T, Fléjou JF, Trédaniel J, Régnard JF, Damotte D, Alifano M, Forgez P.

Oncotarget. 2014 Sep 30;5(18):8252-69.

9.

Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.

Dupouy S, Doan VK, Wu Z, Mourra N, Liu J, De Wever O, Llorca FP, Cayre A, Kouchkar A, Gompel A, Forgez P.

Oncotarget. 2014 Sep 30;5(18):8235-51.

10.

Thymoquinone inhibits proliferation and invasion of human nonsmall-cell lung cancer cells via ERK pathway.

Yang J, Kuang XR, Lv PT, Yan XX.

Tumour Biol. 2015 Jan;36(1):259-69. doi: 10.1007/s13277-014-2628-z. Epub 2014 Sep 20.

PMID:
25238880
11.

The new Back to Basics section: emerging concepts in basic and translational medicine.

Königshoff M.

Eur Respir J. 2014 Aug;44(2):297-8. doi: 10.1183/09031936.00107914. No abstract available.

PMID:
25082908
12.

Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.

Qu Y, Wu X, Yin Y, Yang Y, Ma D, Li H.

J Exp Clin Cancer Res. 2014 Jun 17;33:52. doi: 10.1186/1756-9966-33-52.

13.

Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors.

Szokol B, Gyulavári P, Kurkó I, Baska F, Szántai-Kis C, Greff Z, Orfi Z, Peták I, Pénzes K, Torka R, Ullrich A, Orfi L, Vántus T, Kéri G.

ACS Med Chem Lett. 2014 Jan 30;5(4):298-303. doi: 10.1021/ml4003309. eCollection 2014 Apr 10.

14.

Fibroblasts weaken the anti-tumor effect of gefitinib on co-cultured non-small cell lung cancer cells.

Yong X, Wang P, Jiang T, Yu W, Shang Y, Han Y, Zhang P, Li Q.

Chin Med J (Engl). 2014;127(11):2091-6.

PMID:
24890158
15.

Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Wu M, Yuan Y, Pan YY, Zhang Y.

Mol Med Rep. 2014 Aug;10(2):931-8. doi: 10.3892/mmr.2014.2243. Epub 2014 May 16.

PMID:
24840891
16.

RAC1 inhibition as a therapeutic target for gefitinib-resistant non-small-cell lung cancer.

Kaneto N, Yokoyama S, Hayakawa Y, Kato S, Sakurai H, Saiki I.

Cancer Sci. 2014 Jul;105(7):788-94. doi: 10.1111/cas.12425. Epub 2014 May 15.

PMID:
24750242
17.

Peroxisome proliferator-activated receptor γ agonist efatutazone impairs transforming growth factor β2-induced motility of epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer cells.

Serizawa M, Murakami H, Watanabe M, Takahashi T, Yamamoto N, Koh Y.

Cancer Sci. 2014 Jun;105(6):683-9. doi: 10.1111/cas.12411. Epub 2014 May 10.

PMID:
24698130
18.
19.

Growth and survival of lung cancer cells: regulation by kallikrein-related peptidase 6 via activation of proteinase-activated receptor 2 and the epidermal growth factor receptor.

Michel N, Heuzé-Vourc'h N, Lavergne E, Parent C, Jourdan ML, Vallet A, Iochmann S, Musso O, Reverdiau P, Courty Y.

Biol Chem. 2014 Sep;395(9):1015-25. doi: 10.1515/hsz-2014-0124.

PMID:
24643912
20.

Short-course treatment with gefitinib enhances curative potential of radiation therapy in a mouse model of human non-small cell lung cancer.

Bokobza SM, Jiang Y, Weber AM, Devery AM, Ryan AJ.

Int J Radiat Oncol Biol Phys. 2014 Mar 15;88(4):947-54. doi: 10.1016/j.ijrobp.2013.12.038.

PMID:
24606853
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk